NR5A2
MOLECULAR TARGETnuclear receptor subfamily 5 group A member 2
NR5A2 (nuclear receptor subfamily 5 group A member 2) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting NR5A2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Anisomycin | 1.10 | 2 |
| 2 | Azacitidine | 1.10 | 2 |
| 3 | Azacitidine | 1.10 | 2 |
| 4 | cycloheximide | 1.10 | 2 |
| 5 | Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. | 1.10 | 2 |
| 6 | Digoxigenin 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide. | 1.10 | 2 |
| 7 | Digoxin | 1.10 | 2 |
| 8 | Lanatosides Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale, | 1.10 | 2 |
| 9 | Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide. | 1.10 | 2 |
| 10 | Tubercidin | 1.10 | 2 |
| 11 | tyrphostin 9 | 1.10 | 2 |
| 12 | Methylene Blue | 0.69 | 1 |
| 13 | Progesterone | 0.69 | 1 |
| 14 | Aldosterone | 0.69 | 1 |
| 15 | Methotrexate | 0.69 | 1 |
| 16 | Cilostazol | 0.69 | 1 |
| 17 | clofilium tosylate | 0.69 | 1 |
| 18 | dihydrorotenone | 0.69 | 1 |
| 19 | Ethidium | 0.69 | 1 |
| 20 | Gemfibrozil | 0.69 | 1 |
| 21 | Triiodothyronine | 0.69 | 1 |
| 22 | vinblastine sulfate | 0.69 | 1 |
About NR5A2 as a Drug Target
NR5A2 (nuclear receptor subfamily 5 group A member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented NR5A2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
NR5A2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.